Innovent
Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis
Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance
Innovent Biologics Reports Promising Results in Early-Stage Study of Bispecific Antibody IBI363 in Lung Cancer Patients
Innovent Biologics, IBI363, Bispecific Antibody, Lung Cancer, Early-Stage Study, PD-1/IL-2 α-bias, Non-Small Cell Lung Cancer (NSCLC)
Innovent Achieves Another Phase 3 Victory in China for Next-Generation Lilly GLP-1 Drug
Innovent Biologics, Lilly, GLP-1, Mazdutide, Phase 3 Trial, Type 2 Diabetes, Weight Loss, China
Innovent Biologics’ Picankibart Achieves Success in Phase III CLEAR-1 Study for Moderate to Severe Plaque Psoriasis
Innovent Biologics, picankibart, Phase III CLEAR-1 study, moderate to severe plaque psoriasis, IL-23p19 class, new drug application, Center for Drug Evaluation, National Medical Product Administration.
Innovent to Submit IL-23 Psoriasis Drug to Chinese Regulators Following Phase 3 Success
Innovent, IL-23, psoriasis, picankibart, phase 3, China, regulatory submission, plaque psoriasis, CLEAR-1 study
Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management
Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.